Chuyuan Wang, Jing Qiao, Shanshan Liu, Sichen Piao, Yun Zhou, Yuedong Hu, Chao Wan, Yizhou Sun, Hong Ning, Lei Chen, He Zhang, Ruolin Hu, Haoyu Wang, Weiwei Wang, Lei Zhao, Jinyuan Mao, Min Li, Weiping Teng, Zhongyan Shan, Yushu Li
PURPOSE: Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease. However, limited studies have investigated the actual efficacy of selenium in GO therapy. This longitudinal study explored the effect of selenium on QOL and prognosis of patients with mild-to-moderate GO. METHODS: We conducted a 5-year prospective controlled cohort clinical trial to determine the effect of selenium on 74 patients with mild-to-moderate GO. Patients received selenium yeast or placebo orally for 6 months and were followed up at 6 months and at 5 years by biochemical examination, ophthalmologist evaluation and QOL questionnaire to assess oculopathy and QOL...
January 10, 2024: Endocrine